Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PUMA BIOTECHNOLOGY, INC.

(PBYI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Insider Trends: Puma Biotechnology Insider Continues 90-Day Selling Trend

06/15/2021 | 06:17pm EDT


© MT Newswires 2021
All news about PUMA BIOTECHNOLOGY, INC.
07/22PUMA BIOTECHNOLOGY : to Host Conference Call to Discuss Second Quarter Financial..
BU
07/14PUMA BIOTECHNOLOGY : Departure of Directors or Principal Officers; Election of D..
PU
07/14PUMA BIOTECHNOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/14Puma Biotechnology, Inc. Appoints Allison Dorval to the Board of Directors an..
CI
07/06KNIGHT THERAPEUTICS : Says Health Canada Approves Neratinib for Treatment of HER..
MT
07/02PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)..
BU
07/01PUMA BIOTECHNOLOGY : Receives FDA Approval for Dose Escalation Label Update to N..
MT
07/01PUMA BIOTECHNOLOGY : FDA Approves Dose Escalation Label Update for Puma Biotechn..
BU
07/01FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® i..
CI
06/25PUMA BIOTECHNOLOGY, INC. : Other Events (form 8-K)
AQ
More news
Financials (USD)
Sales 2021 261 M - -
Net income 2021 -6,62 M - -
Net cash 2021 22,0 M - -
P/E ratio 2021 -31,9x
Yield 2021 -
Capitalization 313 M 313 M -
EV / Sales 2021 1,11x
EV / Sales 2022 0,92x
Nbr of Employees 267
Free-Float 86,4%
Chart PUMA BIOTECHNOLOGY, INC.
Duration : Period :
Puma Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PUMA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 7,75 $
Average target price 10,38 $
Spread / Average Target 33,9%
EPS Revisions
Managers and Directors
Alan H. Auerbach Chairman, President, CEO & Secretary
Maximo F. Nougues Chief Financial Officer
Jay M. Moyes Lead Independent Director
Troy E. Wilson Independent Director
Adrian M. Senderowicz Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PUMA BIOTECHNOLOGY, INC.-24.46%389
MODERNA, INC.233.90%88 312
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.39.02%47 022
CELLTRION, INC.-25.21%32 170
SEAGEN INC.-16.87%28 525